| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697363 | Bulletin du Cancer | 2016 | 8 Pages |
Abstract
This study suggests a clinical benefit of EP, with a better toxicity's management of sorafenib, leading to less dose reduction. Different types of EP should be compared prospectively, focusing on quality of life.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Angélique Brunot, Amel M'Sadek, Florence Le Roy, Marielle Duval, Samuel Le Sourd, Elodie Ventroux, Laurence Crouzet, Anne Guillygomarc'h, Eveline Boucher, Nadine Lelievre, Brigitte Laguerre, Julien Edeline,